Cargando…

Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential

Factor VIII (FVIII) functions as a cofactor of FIXa for FX activation in the intrinsic tenase complex. The 1811-1818 region in the FVIII A3 domain was observed to contribute to FIXa binding, and the K1813A/K1818A mutant increased the binding affinity for FIXa. The current study aims to identify muta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakajima, Yuto, Takeyama, Masahiro, Oda, Akihisa, Shimonishi, Naruto, Nogami, Keiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139940/ https://www.ncbi.nlm.nih.gov/pubmed/36322904 http://dx.doi.org/10.1182/bloodadvances.2022008187

Ejemplares similares

Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations
por: Shimonishi, Naruto, et al.
Publicado: (2023)

Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage
por: Yamada, Yuya, et al.
Publicado: (2022)

Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target
por: Ankrom, Wendy, et al.
Publicado: (2016)

Molecular Dynamics Simulation Study of the Selective Inhibition of Coagulation Factor IXa over Factor Xa
por: Yoon, Hyun Jung, et al.
Publicado: (2023)

Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity
por: Sampei, Zenjiro, et al.
Publicado: (2014)

Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial
por: Takeyama, Masahiro, et al.
Publicado: (2023)

The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19
por: Onishi, Tomoko, et al.
Publicado: (2022)

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro
por: Noguchi-Sasaki, Mariko, et al.
Publicado: (2018)

Half-Yearly Report of the Progress of Medicine, from January to June, 1813: No. VIII
Publicado: (1813)

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
por: Kitazawa, Takehisa, et al.
Publicado: (2017)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
por: Bashar, Saima, et al.
Publicado: (2023)

SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa
por: Childers, Kenneth C., et al.
Publicado: (2022)

A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa
por: Kundu, Sibsankar, et al.
Publicado: (2021)

Mechano-covalent protection of coagulation factor VIII by von Willebrand factor
por: Butera, Diego, et al.
Publicado: (2022)

Comprehensive coagulation and fibrinolytic potential in the acute phase of pediatric patients with idiopathic nephrotic syndrome evaluated by whole blood-based rotational thromboelastometry
por: Ishikawa, Tomoaki, et al.
Publicado: (2022)

Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII
por: Sayyadipour, Fatemeh, et al.
Publicado: (2020)

Dimeric Organization of Blood Coagulation Factor VIII bound to Lipid Nanotubes
por: Dalm, Daniela, et al.
Publicado: (2015)

Human coagulation factor VIII domain-specific recombinant polypeptide expression
por: Choi, Su Jin, et al.
Publicado: (2015)

Study on Coagulation Factor VIII and Fibrinogen Levels in Patients with Thyroid Disorders
por: Thoyyib, Muhammed, et al.
Publicado: (2018)

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII
por: Firrman, Jenni, et al.
Publicado: (2020)

Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease
por: Pradhan-Sundd, Tirthadipa, et al.
Publicado: (2021)

Characterization and visualization of murine coagulation factor VIII-producing cells in vivo
por: Hayakawa, Morisada, et al.
Publicado: (2021)

Determination of Hexapeptide ALA-ASP-LEU-LYS-PRO-THR by MALDI MS
por: Olejnik, Anna, et al.
Publicado: (2012)

Computational Prediction of the Protonation Sites of Ac-Lys-(Ala)n-Lys-NH2 Peptides through Conceptual DFT Descriptors
por: Sastre, Sebastián, et al.
Publicado: (2017)

Regulation of collective cell migration by RhoGAP myosin IXA
por: Omelchenko, Tatiana
Publicado: (2012)

Aptamer-based factor IXa inhibition preserves hemostasis and prevents thrombosis in a piglet model of ECMO
por: Reed, Christopher R., et al.
Publicado: (2021)

Richard Wagner 1813-1883
por: Norman, Jessye

Maturation of coagulation factor IX during Xase formation as deduced using factor VIII‐derived peptides
por: Fang, Han, et al.
Publicado: (2019)

Detection of Fibrinogen and Coagulation Factor VIII in Plasma by a Quartz Crystal Microbalance Biosensor
por: Yao, Chunyan, et al.
Publicado: (2013)

Mutations in Coagulation Factor VIII Are Associated with More Favorable Outcome in Patients with Cutaneous Melanoma
por: Ping, Zheng, et al.
Publicado: (2017)

Protein residue network analysis reveals fundamental properties of the human coagulation factor VIII
por: Lopes, Tiago J. S., et al.
Publicado: (2021)

His-Ala-Phe-Lys peptide from Burkholderia arboris possesses antifungal activity
por: Zhu, Huajie, et al.
Publicado: (2022)

Von Willebrand factor and coagulation factor VIII in Moyamoya disease associated with Graves' disease: A case report
por: Ren, Shou-Chen, et al.
Publicado: (2016)

Mice deficient in the anti-haemophilic coagulation factor VIII show increased von Willebrand factor plasma levels
por: Kiouptsi, Klytaimnistra, et al.
Publicado: (2017)

The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V
por: Pablo-Moreno, Juan A. De, et al.
Publicado: (2022)

Covalent docking and molecular dynamics simulations reveal the specificity-shifting mutations Ala237Arg and Ala237Lys in TEM beta-lactamase
por: da Silva, Gabriel Monteiro, et al.
Publicado: (2022)

Limited Promiscuity of HLA-DRB1 Presented Peptides Derived of Blood Coagulation Factor VIII
por: van Haren, Simon D., et al.
Publicado: (2013)

Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution
por: Shim, Ye Jee, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i1t5dkuk5ojffuedsk7tkd6tqv